Results 141 to 150 of about 19,019 (189)
Temporary increase in circulating replication-competent latent HIV-infected resting CD4+ T cells after switch to an integrase inhibitor based antiretroviral regimen. [PDF]
EBioMedicineFerreira RC, Reynolds SJ, Capoferri AA, Baker OR, Brown EE, Klock E, Miller J, Lai J, Saraf S, Kirby C, Lynch B, Hackman J, Gowanlock SN, Tomusange S, Jamiru S, Anok A, Kityamuweesi T, Buule P, Bruno D, Martens C, Rose R, Lamers SL, Galiwango RM, Poon AFY, Quinn TC, Prodger JL, Redd AD. +26 moreeuropepmc +1 more sourceGenetic Diversity and Naturally Polymorphisms in HIV Type 1 Integrase Isolates from Maputo, Mozambique: Implications for Integrase Inhibitors [PDF]
, 2012 Michelli F. Oliveira, Dulce B. Ramalho, Celina Monteiro Abreu, Adolfo Vúbil, Nédio Mabunda, Nália Ismael, Cidia Francisco, Ilesh Jani, Amílcar Tanuri +8 moreopenalex +1 more sourceRisk Factors for Weight Gain Following Switch to Integrase Inhibitor-Based Antiretroviral Therapy. [PDF]
Clin Infect Dis, 2020 Lake JE, Wu K, Bares SH, Debroy P, Godfrey C, Koethe JR, McComsey GA, Palella FJ, Tassiopoulos K, Erlandson KM. +9 moreeuropepmc +1 more sourceIn VitroAntiretroviral Properties of S/GSK1349572, a Next-Generation HIV Integrase Inhibitor
, 2010 Masanori Kobayashi, Tomokazu Yoshinaga, Takahiro Seki, Chiaki Wakasa-Morimoto, Kevin Brown, Robert G. Ferris, Scott A. Foster, Richard Hazen, Shigeru Miki, Akemi Suyama-Kagitani, Shinobu Kawauchi-Miki, Teruhiko Taishi, Takashi Kawasuji, Brian A. Johns, Mark Underwood, Edward P. Garvey, Akihiko Sato, Tamio Fujiwara +17 moreopenalex +1 more sourceInvestigation of furo[2,3-h]- and pyridazino[3,4-f]cinnolin-3-ol scaffolds as substrates for the development of novel HIV-1 integrase inhibitors
, 2011 Mohamed F. Y. Gomaa, Nicolino Pala, Marco Derudas, Jehan Abd-Elrazik Hasanen, Elsayed H. Eltamany, Paola Casule, Alberto Mariani, Mario Sechi +7 moreopenalex +2 more sources